Tag: Novo Nordisk A/S

Eli Lilly’s GLP-1 growth is only getting started as Novo Nordisk braces for a decline in 2026

Eli Lilly blows past quarterly estimates, posts strong outlook as Zepbound and Mounjaro sales soar

Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial

Eli Lilly CEO says Medicare coverage of obesity drugs could ‘change the game’ for upcoming pill launch

Eli Lilly plans $3.5 billion manufacturing plant in Pennsylvania to make next-generation obesity injections

What obesity drugmakers see next in the market: More pills, easier access and drug combinations

Healthy Returns: Structure Therapeutics CEO on its obesity pill, combinations and future of GLP-1s

Drug pricing, patent losses and deals: Here’s what pharma execs see ahead in the industry

Novo Nordisk shares rise 5% after Wegovy obesity pill has ‘solid’ launch

Healthy Returns: Novo Nordisk CEO on GLP-1 pricing, and more insights from the JPM conference